Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006) - Full Text View

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

This study has been completed.

Sponsored by:	Sirion Therapeutics, Inc.
Information provided by:	Sirion Therapeutics, Inc.
ClinicalTrials.gov Identifier:	NCT00549289

Purpose

The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.

Condition	Intervention	Phase
Dry Eye Syndromes	Drug: cyclosporine A	Phase III

ChemIDplus related topics:

Cyclosporine Cyclosporin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Open Label, Single Group Assignment

Eligibility

Ages Eligible for Study:	2 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Diagnosis of dry eye syndrome

Exclusion Criteria:

Intraocular or refractive surgery in the study eye within 3 months prior to study start
Unwilling to discontinue use of contact lenses during the study
Pregnancy or lactation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00549289

Locations


United States, Georgia
	Clayton Eye Center
	Morrow, Georgia, United States, 30260

Sponsors and Collaborators

Sirion Therapeutics, Inc.

Investigators


Study Chair:	Roger Vogel	Sirion Therapeutics

More Information

Study ID Numbers:	ST-603-006
First Received:	October 24, 2007
Last Updated:	October 24, 2007
ClinicalTrials.gov Identifier:	NCT00549289
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Cyclosporine

Clotrimazole

Miconazole

Eye Diseases

Tioconazole

Lacrimal Apparatus Diseases

Dry Eye Syndromes

Cyclosporins

Additional relevant MeSH terms:

Anti-Infective Agents

Disease

Molecular Mechanisms of Pharmacological Action

Immunologic Factors

Physiological Effects of Drugs

Enzyme Inhibitors

Immunosuppressive Agents

Pharmacologic Actions

Pathologic Processes

Syndrome

Antifungal Agents

Therapeutic Uses

Antirheumatic Agents

Dermatologic Agents

ClinicalTrials.gov processed this record on October 17, 2008